Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Inspire Medical Systems (INSP)

Inspire Medical Systems raises 2024 EPS guidance to $0.60-$0.80 on Q2 revenue up 30%

Positive Impact 4 of 5 earnings Written later

Inspire Medical Systems reported second-quarter 2024 revenue of $195.9 million, up 30% from a year earlier, and net income of $9.8 million, compared with a net loss of $12.0 million a year earlier. The company raised its full-year 2024 revenue and diluted EPS guidance and authorized its first share repurchase program, of up to $150.0 million.

Key points

  • Q2 2024 revenue $195.9 million, up 30% from $151.1 million; diluted EPS $0.32 vs. a $0.41 loss a year earlier
  • Full-year 2024 revenue guidance raised to $788 million-$798 million from $783 million-$793 million
  • Full-year 2024 diluted EPS guidance raised to $0.60-$0.80 from $0.10-$0.20, excluding any share repurchases
  • Board authorized repurchase of up to $150.0 million of common stock, the first in company history

The filing

CompanyInspire Medical Systems (INSP)
Form8-K, current report
Filed with the SECAug 6, 2024, 4:04 PM ET
Accession number0001609550-24-000042

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.